Portage Biotech
47 Avenue Road
Suite 200
Toronto
Ontario
M5R 2G3
Canada
Tel: 416-929-1806
Fax: 416-929-6612
Website: http://portagebiotech.com/
107 articles with Portage Biotech
-
Portage Biotech to Present at Oppenheimer’s 33rd Annual Healthcare Conference
3/7/2023
Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that the Company’s management team will be presenting virtually at Oppenheimer’s 33rd Annual Healthcare Conference on March 13-15, 2023.
-
Portage Biotech Announces Results for Fiscal Quarter Ended December 31, 2022
3/1/2023
Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced financial results for the fiscal quarter ended December 31, 2022.
-
Portage Biotech Hosting Key Opinion Leader Event on Targeting the Adenosine Pathway in Cancer
2/27/2023
Portage Biotech Inc. announced that it will host a key opinion leader webinar on targeting the adenosine pathway in cancer on Thursday, March 9, 2023 at 10:30 am Eastern Time.
-
Portage Biotech to Participate in Citi's 2023 Virtual Oncology Leadership Summit
2/15/2023
Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that the Company’s management team will participate in a fireside chat at Citi's 2023 Virtual Oncology Leadership Summit taking place on Febrarury 21 – 23, 2023.
-
JP Morgan week is shaping up to approximate pre-pandemic attendance levels as executives return to San Francisco after two years of COVID-19-enforced absences.
-
Portage Biotech Announces Results for Fiscal Quarter Ended September 30, 2022
11/29/2022
Portage Biotech Inc., (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced financial results for the fiscal quarter ended September 30, 2022.
-
Many biopharma companies raised funds in 2022, but not enough to reach their next milestone. Investors have been constricting investments, so companies needing additional funding require a larger toolbox.
-
Portage Biotech Presents Updated Data on the Phase 1/2 Trial Evaluating PORT-2 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
11/10/2022
Portage Biotech Inc. announced the presentation of updates from its ongoing Phase 1/2 study of PORT-2, an invariant natural killer T cell agonist for patients with non-small cell lung cancer and advanced melanoma, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting.
-
Portage Biotech Provides Research and Development Update
9/14/2022
Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival, today provided an update on its research and development programs for its expanded portfolio of immuno-oncology assets, and outlined its forward-looking clinical development goals for the next two years.
-
Portage Biotech to Present at Upcoming September 2022 Investor Conferences
9/8/2022
Portage Biotech Inc. announced that the Company’s management team will be presenting at the following upcoming investor conferences.
-
Portage Biotech Announces Results for Fiscal Quarter Ended June 30, 2022
8/29/2022
Portage Biotech Inc. today announced financial results for the fiscal quarter ended June 30, 2022.
-
This week's Movers & Shakers include Arvinas, Inspire and Cambridge Isotope Laboratories all announcing new VP roles, and several others tap new C-suite executives.
-
Portage Biotech Announces Leadership Updates
8/18/2022
Portage Biotech Inc. today announced that Dr. Ian Walters, Chief Executive Officer of Portage, will be appointed Chairman of Portage's Board of Directors.
-
UPDATE -- Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022
8/1/2022
Portage Biotech Inc., a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, announced financial results for the fiscal year ended March 31, 2022.
-
Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022
8/1/2022
Portage Biotech Inc. today announced financial results for the fiscal year ended March 31, 2022.
-
Portage Biotech announced Wednesday that it has inked an acquisition agreement with New York-based Tarus Therapeutics, adding four new candidates to its pipeline.
-
Portage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine Pathway
7/6/2022
Portage Biotech Inc., a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, announced that it has signed an agreement to acquire Tarus Therapeutics, a private company developing adenosine receptor antagonists.
-
Portage Biotech Summarizes Data Presented at ASCO 2022 Annual Meeting Including Updates from Ongoing PORT-2 Study
6/6/2022
Portage Biotech Inc. announced that the Company presented early data from its Phase 1/2 study of PORT-2, an invariant natural killer T cell agonist for patients with melanoma and non-small cell lung cancer, at the 2022 American Society of Clinical Oncology meeting.
-
Portage Biotech Enters Cooperative Research and Development Agreement with U.S. National Cancer Institute and Stimunity
4/25/2022
Portage Biotech Inc. (NASDAQ: PRTG), today announced that it has entered a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the U.S. National Institutes of Health, and Stimunity, S.A.S, an affiliate of Portage with experience in the preclinical development of stimulator of interferon genes (STING) agonists for cancer immunotherapy and infectious diseases.
-
BioSpace looked at some of the efforts to improve the host system’s immune response, as well as others to improve allogeneic or autologous cell transplants.